A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy
NCT ID: NCT05828875
Last Updated: 2023-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2023-08-01
2024-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer
NCT01216527
Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO
NCT04137679
Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01
NCT03298204
Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer
NCT01670409
Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer
NCT02972372
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
questionnaire investigation
Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The age at the time of radiotherapy is between 18-75 years old, and the age at the time of investigation is\<80 years old;
* Histologically confirmed esophageal squamous cell carcinoma without undergoing surgical resection;
* Received radical chemoradiotherapy/radiotherapy from July 2017 to July 2020, currently alive and without disease progression;
* Radiotherapy dose ≥ 45Gy.
Exclusion Criteria
* Patients who have died at the time of investigation;
* Patients who experience tumor progression within the time frame from the end of radiotherapy to receiving this survey;
* Patients diagnosed with other malignant tumors within the time frame from the end of radiotherapy to receiving this survey;
* Patients with incorrect contact information and missing visits
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Medical University Cancer Institute and Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Qingsong Pang, PHD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
bc2022181
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.